4582 SymBio Pharmaceuticals
- 230
- +42+22.34%
SymBio Pharmaceuticals News
Emerging Market Outlook: Will funds flow towards major processing, bio, and earnings stocks as the Growth Market 250 Index enters a battle to break through the 200-day moving average?
Emerging markets saw an inflow of funds due to the sharp decline in large cap stocks over the weekend, causing an increase in emerging markets this week. During the same period, the growth market index rose significantly by +2.60%, and the growth market 250 index rose by +2.99%, compared to the Nikkei average of +0.68%. Although trading volume in emerging markets declined at the beginning of the week, a stagnant market with little price fluctuations occurred in both the growth market index and the growth market 250 index. However, at the end of the week, large cap stocks plummeted more than 1000 yen due to the decline of the Nikkei average, while emerging markets saw
The TOPIX Gross Index rose significantly, with growth core 20 stocks all expanding gains.
Tokyo Stock Exchange Growth Market Index is at 868.64, up 24.20 points, with a volume of 0.2 billion 33.78 million shares and a trading value of 185.1 billion yen. The TSE Growth Market 250 Index is at 677.13, up 21.27 points, with a volume of 0.1 billion 77.28 million shares and a trading value of 159.2 billion yen. Today's growth market has seen both the TSE Growth Market Index and TSE Growth Market 250 Index continue to rise significantly. The number of rising stocks is 291, the number of falling stocks is 245, and unchanged is 45. The US stock market on the 11th was mixed. The Dow average was up 32.39 dollars.
Stocks hitting the upper or lower price limit in the afternoon session.
■Stocks that hit the upper limit＜194A＞WOLVES HAND ＜4196＞NEO MARKETING ＜4288＞AZJENT ＜4443＞Sansan ＜4582＞Shin-Biyo Seiyaku ＜5250＞Main Board Strategy ＜6532＞Baycurrent Consulting■Stocks that hit the lower limit＜4586＞Medirex※includes temporary upper and lower limits (indicative value)
Ranking of Volume Change Rate (as of 1:00 pm) - Tama Home, Bay Current, etc. are ranked.
* In the volume change rate ranking, you can find out the interests of market participants, such as trends in speculation, by comparing the volume of the past five days with the volume on the day of delivery. * Top volume change rate [as of July 12, 13:32] (Comparison of average volume of the past 5 days) Code=>Stock Name=>Volume=>5-Day Average Volume=>Volume Change Rate=>Stock Price Change Rate <4582> Simbio 12361000 154980.36 310.84% 0.1755% <1419>
The TOPIX Large Cap Index rebounded for the first time in three days, with large-cap stocks dominating and continuing to consolidate at the 75-day moving average.
Tokyo Stock Exchange Growth Market index 844.44 +1.26 / volume 0.1 billion 88.63 million shares / trading value 133.1 billion yen. Tokyo Stock Exchange Growth Market 250 index 655.86 +1.35 / volume 0.1 billion 27.73 million shares / trading value 110.9 billion yen. Today's growth market rebounded for the first time in 3 days, with the Tokyo Stock Exchange Growth Market index and the Tokyo Stock Exchange Growth Market 250 index both rising. There were 291 gainers, 245 losers, and 45 unchanged. The US stock market rose on the 10th. The Dow Jones Industrial Average was up 429.39 dollars.
The TOPIX Global Market 250 index rebounded for the first time in four days, led by the main stocks.
Tokyo Stock Exchange Growth Market Index 842.51 +8.29 / Volume 216,130,000 shares / Trading value 132.9 billion yen. Tokyo Stock Exchange Growth Market 250 Index 653.03 +6.99 / Volume 147,600,000 shares / Trading value 83.0 billion yen. Today's growth market saw a rebound for both Tokyo Stock Exchange Growth Market Index and Tokyo Stock Exchange Growth Market 250 Index after a 4-day decline. The number of rising stocks was 327, the number of declining stocks was 225, and the unchanged stocks were 35. The US stock market on the 2nd continued to rise. The Dow Jones Industrial Average was up 162.33 dollars (
Ranking of volume change rate (as of 10am) ~ SimBio, metallurgical workers, etc. are ranked.
In the volume change rate ranking, you can understand the interests of market participants, such as trends in speculation, by comparing the average trading volume of the most recent 5 days to the trading volume on the day of delivery. ■ Top Volume Change Rate [As of 10:32 on July 3] (Comparison of average trading volume for the most recent 5 days) Stock code Stock name Volume 5-day average volume Volume change rate Stock price change rate <4582> Shinbio 3748400 105607.5 212.85% 0.080
Company Research Report: SymBio Pharmaceuticals (4582)
Volume change rate ranking (9am)~ including Systemna, KADOKAWA ranking in.
* In volume change rate rankings, by comparing the average volume of the past 5 days with the volume on the day of delivery, market participants can understand the trends in trading and other interests. * Top volume change rates [As of 9:35 on June 24] (Comparison with the average volume of the past 5 days) Ticker code Name Volume 5-day average volume Volume change rate Stock price change rate <4221> Okura Industrial 142,100 107,185.08 139.3% 0.0133
Part 2 of the previous day's moving stocks include SLD, MagMag, Age.
Stock Name <Code> 12-day closing price ⇒ Previous day comparison view garages <3180> 1689 -93 Negative view continues on the slowdown in this year's earnings growth rate. Nippon Steel <5631> 4374-196 The sense of exhaustion with the announcement of the midterm plan takes precedence. Daiichi Sankyo <4568> 5626-144 Is profit-taking selling in anticipation of the weight of the upside in the high price range? Pan-Pacific HD <7532> 3802-91 Reacts poorly to a strong existing store on the 11th and falls below the 25-day moving average on the 12th. Asahi Intec <
Active and newly listed stocks during the morning session.
*Medical Data Vision <3902> 562 +57 SBIHD's additional share acquisition is reported. *Laxur <4384> 984 +70 announced good third quarter performance and the implementation of the first dividend. *Daidan <1980> 3320 +210 expected to expand data center projects. * Mimaki Engineering <6638> 2206 +134 Will short cover be strengthened by the daily rise in stock prices? *Wacoal HD <3591> 4165 +2053 D
Shin-Bio Pharmaceuticals achieved FPI (first patient in) in the Phase 2a clinical trial of the injection Brincidofovir.
On June 11, 2024 (Central Time in the United States), the first case was registered in the Phase 2a clinical trial of the injection drug brincidofovir (hereinafter referred to as "BCV"), which is being conducted in the United States by Shin BioPharmaceuticals Co., Ltd. (4582) for cytomegalovirus (CMV) infection in patients after hematopoietic stem cell transplantation. The same trial is a Phase 2a trial for immunocompromised adenovirus infection currently underway.
The TOPIX index has risen for 3 consecutive days, with main stocks performing well and breaking through the 25-day moving average for the first time since March 22nd.
The TSE Growth Market Index was 814.17, up 6.39, with a volume of 154.12 million shares and a turnover of 147.3 billion yen. The TSE Growth Market 250 index was 631.49, up 5.71, with a volume of 163.3 million shares and a turnover of 105.4 billion yen. Today's growth market saw the TSE Growth Market and TSE Growth Market 250 indexes rise for the third consecutive day. The number of rising stocks was 280, the number of falling stocks was 251, and the unchanged was 40. On the 10th, the US stock market rebounded. Dow Inc increased by $69.05 (+0)
Emerging Markets Digest: Shionogi Pharmaceuticals, Ridge Eye reached their limit up price.
<4019> Starting lineup 580, up for 73 consecutive days. The engagement management platform service "TUNAG" has announced that it has been adopted by Toho Gas Network and is considered a good material. TUNAG is an application that can comprehensively implement measures to improve engagement. In using "TUNAG", Toho Gas challenges its workplace members to expand their business areas, develop technology, and work on DX while ensuring stable gas supply in urban areas.
Stocks that hit the daily limit up or down in the morning session.
Stop-high <2929>, Phama Foods <4582>, Sinbio Pharmacist <7073>, Jayke <7083>, AHC Group <7116>, Daiwa Communications <7608>, SK Japan. Stop-loss *Includes temporary stop-high/low (indicative value).
Synbio Pharmaceuticals Research Memo (12): Aiming to grow as a global specialty pharma as a long-term goal
■Future outlook 2. Long-term strategy Synbio Pharmaceuticals ＜4582＞ aims to grow as a global specialty pharma as a long-term goal, and wants to increase domestic and overseas sales ratios of 50%, respectively, by 2030. Domestically, in addition to “treaxine (R),” it is a strategy to expand sales by listing new items and BCVs to be introduced in the future, and to expand sales overseas by launching at least 2 items with BCV. As a BCV platform deployment
Synbio Pharmaceuticals Research Memo (10): Policy to secure cash on hand of 5.5 to 6.5 billion yen as a guide
■Performance Trends 2. Financial Status The total assets of Synbio Pharmaceuticals＜4582＞ at the end of the 2023/12 fiscal year decreased 2,263 million yen from the end of the previous fiscal year to 8,170 million yen. Looking at the main factors of change, cash and deposits increased by 234 million yen in current assets, while accounts receivable decreased by 1,171 million yen. As for fixed assets, tangible fixed assets decreased by 69 million yen and software by 222 million yen, respectively, due to the recording of impairment losses, and deferred tax assets decreased by 744 million yen. What is the total debt
Synbio Pharmaceuticals Research Memo (9): Sales declined drastically in the 2023/12 fiscal year due to the penetration of generic drugs and falling drug prices
■Earnings Trends 1. Financial Overview for the Fiscal Year Ending 2023/12 The consolidated financial results for the fiscal year ending 2023/12 of Synbio Pharmaceuticals (4582) were sales down 44.1% from the previous fiscal year to 5,589 million yen, operating losses of 811 million yen (profit of 1,963 million yen in the previous fiscal year), ordinary losses of 736 million yen (same profit of 1,999 million yen), and net loss attributable to parent company shareholders was 1,962 million yen (profit of 1,179 million yen) for the first time in 4 periods, 3 The loss was recorded for the first time in the period. Sales are new models
Synbio Pharmaceuticals Research Memo (8): Rigocertib is exploring development possibilities in combination with other agents
■Other pipeline trends for Synbio Pharmaceuticals＜4582＞ 2. “Ligosertib” (injection/oral agent) and “rigocertib” are anticancer drug candidates having a unique multi-kinase inhibitory effect (action that causes cancer cells to die by inhibiting multiple kinases involved in the proliferation, invasion, and metastasis of cancer cells). An international joint phase 3 clinical trial (INSPIRE trial) for myelodysplastic syndrome (MDS) was conducted at the introducer Onconova, 2020
Synbio Pharmaceuticals Research Memo (7): Market share of treaxine (R) is expected to decline moderately due to entry into generic pharmaceuticals
■Other pipeline trends for Synbio Pharmaceuticals＜4582＞ 1. “Treaxine (R)” (generic name: bendamustine hydrochloride) and “treaxine (R)” are anticancer drugs for malignant lymphoma. Malignant lymphoma is a disease in which lymphocytes, which are a type of white blood cell, become cancerous (tumours) and form lumps (tumors) in lymph nodes and organs, and also occurs from lymph nodes distributed throughout the body and organs other than lymph nodes (stomach, intestines, thyroid, spinal cord, lungs, liver, skin, eyes, etc.). Of blood cancer
Analysis
Price Target
No Data
